Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes ...

Novo Nordisk reported a 26% increase in both sales and operating profit for 2024, reflecting its continued expansion in diabetes and obesity care. The company now serves over 45 million patients ...

functionality that Novo Nordisk has said it intends to add to its smart NovoPen range. The company says it is open to partnering with CGM manufacturers and other diabetes care technology firms ...

so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living with diabetes, obesity, and growth disorders is a welcome step forward. The new PenCycle programme ...

The Danish pharma giant, known for its blockbuster diabetes and weight-loss medications Ozempic and Wegovy, is on track to have its worst week on Wall Street this year. Novo Nordisk shares have ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...